Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 455

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 455
---
 | ​ | ​ | ​ | ​                 | ​ |  5.7% | ​ | ​ |
| Stock Price             | ​ | ​ | ​                             | $ | 10.72 | ​ | ​ | ​ | ​                 | $ | 10.33 | ​ | ​ |
| Exercise Price          | ​ | ​ | ​                             | $ | 11.50 | ​ | ​ | ​ | ​                 | $ | 11.50 | ​ | ​ |

The change in the fair value of the warrant liabilities classified as Level 3 for the three months ended September 30, 2024 and the year ended December 31, 2023 is summarized as follows:

| ​ | Fair value at January 1, 2024    | ​ | ​ | ​ | $ |  168,754 | ​ | ​ |
| ​ | Change in fair value             | ​ | ​ | ​ | ​ |   82,824 | ​ | ​ |
| ​ | Fair value at March 31, 2024     | ​ | ​ | ​ | ​ |  251,578 | ​ | ​ |
| ​ | Change in fair value             | ​ | ​ | ​ | ​ |  -51,045 | ​ | ​ |
| ​ | Fair value at June 30, 2024      | ​ | ​ | ​ | ​ |  200,533 | ​ | ​ |
| ​ | Change in fair value             | ​ | ​ | ​ | ​ | -141,971 | ​ | ​ |
| ​ | Fair value at September 30, 2024 | ​ | ​ | ​ | $ |   58,562 | ​ | ​ |

NOTE 11. SUBSEQUENT EVENTS The Company’s management has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events other than the below that would have required adjustment or disclosure in the financial statements. On October 23, 2024, the parties to the Business Combination Agreement amended the Business Combination Agreement to amend the consideration to be paid in the Transactions to consist of 17.5 million shares of ParentCo’s common stock at $10.00 per share value. On October 30, 2024, as a result of Gaius acquisition of Columbass, Columbass resigned as managing member of the Sponsor, and Iris Equity Holdings